STEROID-RECEPTOR PROFILE IN HUMAN PROSTATE-CANCER METASTASES AS COMPARED WITH PRIMARY PROSTATIC-CARCINOMA

被引:23
作者
EKMAN, P [1 ]
BROLIN, J [1 ]
机构
[1] KAROLINSKA INST,DEPT UROL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN
关键词
ANDROGEN RECEPTORS; PROGESTERONE RECEPTORS AND ESTROGEN RECEPTORS; CANCER;
D O I
10.1002/pros.2990180207
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The steroid receptor profile in seven prostate cancer metastases was compared with the profile in seven primary prostate cancers. The secondaries were all lymph node metastases, obtained during pelvic lymphadenectomy, preceeding radical prostatectomy or irradiation. Cytosol androgen receptor content was higher in metastases, whereas the nuclear androgen receptor content was only one-fourth that in primary cancer. Cytosol progesterone as well as estrogen receptor contents were markedly lower in metastases compared with primary cancer. The steroid receptor profile differed very little between primary cancer and normal tissue. Primary prostatic carcinoma is usually obtained at early stages of the disease, whereas metastases represent a dedifferentiated, more aggressive cell population. This may explain the low amounts of progesterone, estrogen, and nuclear androgen receptor levels. The total androgen receptor content was similar in metastatic and primary disease, however, with a shift towards a cytosolic predominance in metastases. Possibly androgen receptors in metastatic disease are "deactivated."
引用
收藏
页码:147 / 153
页数:7
相关论文
共 32 条
[1]  
ANTAKLY T, 1989, CANCER RES, V49, pS2230
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
BROLIN J, IN PRESS UROL RES
[4]  
Burton K, 1968, METHODS ENZYMOLOGY B, V12, P163
[5]   SCATCHARD PLOTS - COMMON ERRORS IN CORRECTION AND INTERPRETATION [J].
CHAMNESS, GC ;
MCGUIRE, WL .
STEROIDS, 1975, 26 (04) :538-542
[6]  
CHANG C, 1989, J STEROID BIOCHEM, V34, P311
[7]  
DEMURA T, 1988, AM J CLIN ONCOL S2, V1, pS23
[8]  
EKMAN P, 1982, ANTICANCER RES, V2, P163
[9]  
EKMAN P, 1979, CANCER-AM CANCER SOC, V44, P1173, DOI 10.1002/1097-0142(197910)44:4<1173::AID-CNCR2820440402>3.0.CO
[10]  
2-C